MSD launches Clostridium difficile antitoxin in the UK
MSD has launched Zinplava in the UK, offering patients a novel therapeutic option for the prevention of Clostridium difficile recurrence.
Read More
Tag: Zinplava
US nod for Merck’s C.difficile antitoxin
The US Food and Drug Administration has cleared Merck’s Clostridium difficile (CDI) recurrence jab Zinplava after having extended the review period by three month.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
